Cargando…

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, He, Meizhi, Zhou, Yaoyao, Yang, Chen, Wei, Shuyi, Bian, Xiaohui, Christopher, Odong, Xie, Lang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403169/
https://www.ncbi.nlm.nih.gov/pubmed/30873025
http://dx.doi.org/10.3389/fphar.2019.00139
_version_ 1783400529187045376
author Li, Yan
He, Meizhi
Zhou, Yaoyao
Yang, Chen
Wei, Shuyi
Bian, Xiaohui
Christopher, Odong
Xie, Lang
author_facet Li, Yan
He, Meizhi
Zhou, Yaoyao
Yang, Chen
Wei, Shuyi
Bian, Xiaohui
Christopher, Odong
Xie, Lang
author_sort Li, Yan
collection PubMed
description Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients. Methods: A comprehensive search was performed against the Medline/PubMed, Embase, Cochrane Library, Web of Science (WoS) and Scopus databases. Data were extracted with name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cut-off values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score, and statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA). Results: Ten studies were included in this meta-analysis, in which the pooled hazard ratio (HR) showed that PD-L1 expression in tumor cells was significantly associated with a poor overall survival (HR = 1.50, 95% CI 1.05–2.13, P = 0.03). The pooled HR for disease-free survival (DFS) indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95% CI 1.40–4.75, P = 0.002). The pooled odds ratios (ORs) showed that PD-L1 expression was associated with poor differentiation (OR = 3.47, 95% CI 1.37–8.77, P = 0.008) and right colon cancer (OR = 2.38, 95% CI 1.57–3.60, P < 0.0001). However, the expression of PD-L1 was independent of gender, age, tumor size, tumor stage, lymph node metastasis, and tumor-node metastasis stage. Conclusion: This meta-analysis indicated that a high level of PD-L1 expression might be a biomarker for a poor prognosis in CRC patients. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, particularly patients with microsatellite instability high (MSI-H).
format Online
Article
Text
id pubmed-6403169
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64031692019-03-14 The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis Li, Yan He, Meizhi Zhou, Yaoyao Yang, Chen Wei, Shuyi Bian, Xiaohui Christopher, Odong Xie, Lang Front Pharmacol Pharmacology Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients. Methods: A comprehensive search was performed against the Medline/PubMed, Embase, Cochrane Library, Web of Science (WoS) and Scopus databases. Data were extracted with name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cut-off values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score, and statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA). Results: Ten studies were included in this meta-analysis, in which the pooled hazard ratio (HR) showed that PD-L1 expression in tumor cells was significantly associated with a poor overall survival (HR = 1.50, 95% CI 1.05–2.13, P = 0.03). The pooled HR for disease-free survival (DFS) indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95% CI 1.40–4.75, P = 0.002). The pooled odds ratios (ORs) showed that PD-L1 expression was associated with poor differentiation (OR = 3.47, 95% CI 1.37–8.77, P = 0.008) and right colon cancer (OR = 2.38, 95% CI 1.57–3.60, P < 0.0001). However, the expression of PD-L1 was independent of gender, age, tumor size, tumor stage, lymph node metastasis, and tumor-node metastasis stage. Conclusion: This meta-analysis indicated that a high level of PD-L1 expression might be a biomarker for a poor prognosis in CRC patients. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, particularly patients with microsatellite instability high (MSI-H). Frontiers Media S.A. 2019-02-28 /pmc/articles/PMC6403169/ /pubmed/30873025 http://dx.doi.org/10.3389/fphar.2019.00139 Text en Copyright © 2019 Li, He, Zhou, Yang, Wei, Bian, Christopher and Xie. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Yan
He, Meizhi
Zhou, Yaoyao
Yang, Chen
Wei, Shuyi
Bian, Xiaohui
Christopher, Odong
Xie, Lang
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
title The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
title_full The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
title_fullStr The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
title_full_unstemmed The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
title_short The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
title_sort prognostic and clinicopathological roles of pd-l1 expression in colorectal cancer: a systematic review and meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403169/
https://www.ncbi.nlm.nih.gov/pubmed/30873025
http://dx.doi.org/10.3389/fphar.2019.00139
work_keys_str_mv AT liyan theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT hemeizhi theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT zhouyaoyao theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT yangchen theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT weishuyi theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT bianxiaohui theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT christopherodong theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT xielang theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT liyan prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT hemeizhi prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT zhouyaoyao prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT yangchen prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT weishuyi prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT bianxiaohui prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT christopherodong prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis
AT xielang prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis